AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00

AnaptysBio (NASDAQ:ANAB) had its price objective lifted by stock analysts at Guggenheim from $75.00 to $90.00 in a report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price objective indicates a potential upside of 156.05% from the stock’s current price.

ANAB has been the subject of several other research reports. JPMorgan Chase & Co. raised their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Truist Financial boosted their price objective on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of AnaptysBio in a research report on Wednesday, August 14th. Finally, Wedbush reiterated an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a research report on Thursday, September 26th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.64.

AnaptysBio Trading Down 0.6 %

Shares of AnaptysBio stock opened at $35.15 on Monday. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $41.31. The stock has a 50 day moving average of $35.49 and a 200 day moving average of $29.59. The firm has a market cap of $960.26 million, a PE ratio of -5.72 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The company had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. As a group, equities research analysts forecast that AnaptysBio will post -6.84 earnings per share for the current fiscal year.

Insider Activity

In other AnaptysBio news, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of AnaptysBio stock in a transaction that occurred on Wednesday, August 14th. The stock was bought at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the purchase, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was purchased at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the transaction, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 22,440 shares of company stock worth $892,936. Corporate insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently bought and sold shares of the company. nVerses Capital LLC increased its position in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares in the last quarter. Duncan Williams Asset Management LLC acquired a new position in AnaptysBio during the 3rd quarter valued at about $282,000. SG Americas Securities LLC purchased a new stake in AnaptysBio in the third quarter valued at about $405,000. Algert Global LLC boosted its holdings in AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 1,078 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its holdings in AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after acquiring an additional 1,265,891 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.